| Nociceptive neurons protect Drosophila larvae from parasitoid wasps RY Hwang, L Zhong, Y Xu, T Johnson, F Zhang, K Deisseroth, WD Tracey Current biology 17 (24), 2105-2116, 2007 | 503 | 2007 |
| Pickpocket is a DEG/ENaC protein required for mechanical nociception in Drosophila larvae L Zhong, RY Hwang, WD Tracey Current Biology 20 (5), 429-434, 2010 | 309 | 2010 |
| Thermosensory and nonthermosensory isoforms of Drosophila melanogaster TRPA1 reveal heat-sensor domains of a thermoTRP Channel L Zhong, A Bellemer, H Yan, K Honjo, J Robertson, RY Hwang, GS Pitt, ... Cell reports 1 (1), 43-55, 2012 | 262 | 2012 |
| Egg laying decisions in Drosophila are consistent with foraging costs of larval progeny NU Schwartz, L Zhong, A Bellemer, WD Tracey PloS one 7 (5), e37910, 2012 | 98 | 2012 |
| Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis LS Wilson, A Loucks, G Gipson, L Zhong, C Bui, E Miller, M Owen, ... International journal of MS care 17 (2), 74-82, 2015 | 79 | 2015 |
| Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices L Wilson, A Loucks, C Bui, G Gipson, L Zhong, A Schwartzburg, ... Journal of the neurological sciences 344 (1-2), 80-87, 2014 | 79 | 2014 |
| Prevalence and incidence of systemic sclerosis: a systematic review and meta‐analysis L Zhong, M Pope, Y Shen, JJ Hernandez, L Wu International journal of rheumatic diseases 22 (12), 2096-2107, 2019 | 59 | 2019 |
| Cost-effectiveness of niraparib and olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer L Zhong, AT Tran, T Tomasino, E Nugent, JA Smith Journal of managed care & specialty pharmacy 24 (12), 1219-1228, 2018 | 48 | 2018 |
| Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis L Zhong, V Pon, S Srinivas, N Nguyen, M Frear, S Kwon, C Gong, ... PLoS One 8 (5), e64275, 2013 | 44 | 2013 |
| Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer S Lin, S Luo, L Zhong, S Lai, D Zeng, X Rao, P Huang, X Weng International journal of clinical pharmacy 42, 1175-1183, 2020 | 42 | 2020 |
| New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? L Wilson, J Tang, L Zhong, G Balani, G Gipson, P Xiang, D Yu, S Srinivas Journal of Oncology Pharmacy Practice 20 (6), 417-425, 2014 | 31 | 2014 |
| Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels X Weng, S Luo, S Lin, L Zhong, M Li, R Xin, P Huang, X Xu Oncology research 28 (2), 117, 2020 | 28 | 2020 |
| Effectiveness and economic impact of a diabetes education program among adults with type 2 diabetes in South Texas ML Smith, L Zhong, S Lee, SD Towne, MG Ory BMC Public Health 21, 1-12, 2021 | 17 | 2021 |
| Cost-effectiveness analysis of atezolizumab versus durvalumab as first-line treatment of extensive-stage small-cell lung cancer in the USA Y Ionova, W Vuong, O Sandoval, J Fong, V Vu, L Zhong, L Wilson Clinical drug investigation 42 (6), 491-500, 2022 | 16 | 2022 |
| Pickpocket is a DEG L Zhong, RY Hwang, WD Tracey ENaC protein required, 2010 | 15 | 2010 |
| Cost-effectiveness of adding ribociclib to endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer among premenopausal or perimenopausal women E Jeong, C Wang, L Wilson, L Zhong Frontiers in Oncology 11, 658054, 2021 | 12 | 2021 |
| Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer V Le, L Zhong, NL Narsipur, E Hays, DK Tran, K Rosario, L Wilson Journal of Managed Care & Specialty Pharmacy 27 (3), 327-338, 2021 | 12 | 2021 |
| Evaluation of tucatinib in HER2-positive breast cancer patients with brain metastases: a United States-based cost-effectiveness analysis L Dong, S Lin, L Zhong, D Nian, Y Li, R Wang, W Zhou, X Weng, X Xu Clinical Breast Cancer 22 (1), e21-e29, 2022 | 9 | 2022 |
| Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US L Wu, L Zhong Journal of Medical Economics 22 (2), 187-195, 2019 | 9 | 2019 |
| Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM? Y Li, S Lin, L Zhong, S Luo, X Huang, X Huang, L Dong, X Xu, X Weng Pharmacogenomics 22 (13), 809-819, 2021 | 8 | 2021 |
W. Daniel TraceyIndiana University在 indiana.edu 的电子邮件经过验证
